OTCMKTS:BICX BioCorRx (BICX) Stock Price, News & Analysis → I’m officially sounding the alarm. (From Altimetry) (Ad) Free BICX Stock Alerts $1.47 0.00 (0.00%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$1.47▼$1.4750-Day Range$0.75▼$1.5052-Week Range$0.67▼$2.22Volume4 shsAverage Volume1,124 shsMarket Capitalization$13.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get BioCorRx alerts: Email Address Ad InvestorPlaceNew crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. About BioCorRx Stock (OTCMKTS:BICX)BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.Read More BICX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BICX Stock News HeadlinesApril 18, 2024 | finance.yahoo.comBioCorRx Inc. (BICX)April 17, 2024 | americanbankingnews.comBioCorRx (OTCMKTS:BICX) Shares Cross Above Fifty Day Moving Average of $0.98April 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.April 9, 2024 | americanbankingnews.comBioCorRx (OTCMKTS:BICX) Stock Crosses Above Fifty Day Moving Average of $0.90April 3, 2024 | seekingalpha.comBioCorRx receives new patent for novel compound to treat pain, depression, and schizophreniaApril 3, 2024 | globenewswire.comBioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and SchizophreniaApril 2, 2024 | globenewswire.comBioCorRx Reports Business Update for 2023February 29, 2024 | msn.comHow to Win a Business Grant: 4 Entrepreneurs Share Their TipsApril 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.February 28, 2024 | globenewswire.comBioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUDFebruary 22, 2024 | benzinga.comBIOCORRX INC NEW by BioCorRx Inc. Stock (OTC:BICX), Quotes and News SummaryFebruary 13, 2024 | nz.finance.yahoo.comBioCorRx Inc. (BICX) stock price, news, quote & history – Yahoo FinanceFebruary 8, 2024 | finance.yahoo.comBioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of DirectorsJanuary 18, 2024 | msn.comCollective Audience And 3 Other Stocks Under $1 Insiders Are BuyingJanuary 9, 2024 | finance.yahoo.comBioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as PresidentJanuary 4, 2024 | seekingalpha.comTAYNX Transamerica High Yield ESG-Class R4January 3, 2024 | investing.comCheng Fwa Industrial Ltd (5426)November 16, 2023 | finanznachrichten.deBioCorRx Inc: BioCorRx Reports Business Update for the Third Quarter of 2023November 14, 2023 | finance.yahoo.comBioCorRx Reports Business Update for the Third Quarter of 2023October 3, 2023 | benzinga.comBioCorRx President Awarded $14K Worth of Stock OptionsAugust 21, 2023 | finanznachrichten.deBioCorRx Inc: BioCorRx Reports Business Update for the Second Quarter of 2023August 15, 2023 | finance.yahoo.comBioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use DisorderAugust 14, 2023 | finance.yahoo.comBioCorRx Reports Business Update for the Second Quarter of 2023July 29, 2023 | investing.comTokai Holdings Corp (3167)July 29, 2023 | investing.comFukui Bank Ltd (8362)July 28, 2023 | investing.comNissha Printing Co Ltd (7915)July 18, 2023 | investing.comDSC Investment Inc (241520)See More Headlines Receive BICX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCorRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/17/2016Today4/19/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Specialty outpatient clinics, not elsewhere classified Sub-IndustryN/A Current SymbolOTCMKTS:BICX CUSIPN/A CIK1443863 Webwww.biocorrx.com Phone(714) 462-4880FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,770,000.00 Net Margins-4,235.96% Pretax Margin-4,228.35% Return on EquityN/A Return on Assets-623.19% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual Sales$90,000.00 Price / Sales145.04 Cash FlowN/A Price / Cash FlowN/A Book Value($1.14) per share Price / Book-1.29Miscellaneous Outstanding Shares8,880,000Free Float6,978,000Market Cap$13.05 million OptionableNot Optionable Beta0.59 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMs. Lourdes Felix (Age 56)CEO, CFO & Director Comp: $250kMr. Louis Charles Lucido (Age 76)President & Director Comp: $60kDr. George N. FallierasMedical ConsultantKey CompetitorsAesthetic Medical International Holdings GroupNASDAQ:AIHIMACNASDAQ:BACKCheck-CapNASDAQ:CHEKSorrento TherapeuticsNASDAQ:SRNECoeptis TherapeuticsNASDAQ:COEPView All Competitors BICX Stock Analysis - Frequently Asked Questions How have BICX shares performed in 2024? BioCorRx's stock was trading at $0.78 on January 1st, 2024. Since then, BICX stock has increased by 88.5% and is now trading at $1.47. View the best growth stocks for 2024 here. Are investors shorting BioCorRx? BioCorRx saw a drop in short interest in March. As of March 15th, there was short interest totaling 400 shares, a drop of 33.3% from the February 29th total of 600 shares. Based on an average daily volume of 1,400 shares, the days-to-cover ratio is presently 0.3 days. View BioCorRx's Short Interest. When is BioCorRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our BICX earnings forecast. How were BioCorRx's earnings last quarter? BioCorRx Inc. (OTCMKTS:BICX) released its earnings results on Thursday, November, 17th. The company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $0.17 million for the quarter. What other stocks do shareholders of BioCorRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioCorRx investors own include Mondi (MNDI), Alkermes (ALKS), Editas Medicine (EDIT), ImmunoGen (IMGN), Intel (INTC), Netflix (NFLX), Nektar Therapeutics (NKTR), Oracle (ORCL), SS&C Technologies (SSNC) and AT&T (T). How do I buy shares of BioCorRx? Shares of BICX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BICX) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCorRx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.